Komori
Share Issuance and Disposal4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding Completion of Payment for the Issuance of New Shares as Restricted Stock Compensation

The company issued 1,740,000 common shares as restricted stock compensation, and payment was completed on 8 May 2026.

Worth reading
39Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1740000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares as restricted stock compensation

Who receives how much1,740,000Shares

1,740,000 common shares (new shares)

1 representative director: 1,740,000 shares

The lower thin line represents the existing number of shares to which these shares will be added.

¥96 per share
Total issue value

¥167,040,000

Amount of funds to be raised
not disclosed (the shares were issued through an in-kind contribution of compensation receivables and other means, and no subscription amount or estimated net proceeds is stated)
Categories and Number of Persons Covered
1 representative director: 1,740,000 shares
Payment date
8 May 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares as restricted stock compensation
Number of shares to be issued or disposed of1,740,000 common shares (new shares)
Issue price and disposal price¥96 per share
Total issue value¥167,040,000
Amount of funds to be raisednot disclosed (the shares were issued through an in-kind contribution of compensation receivables and other means, and no subscription amount or estimated net proceeds is stated)
Payment date8 May 2026
Intended allottee1 representative director: 1,740,000 shares
Categories and Number of Persons Covered1 representative director: 1,740,000 shares
Items this document does not state (20)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The payment procedures for the issuance of new shares as restricted stock compensation have been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of Payment for the Issuance of New Shares as Restricted Stock Compensation | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori